Lilly's Foundayo Pill Shows Modest Initial Uptake

Key Prescription Data

Eli Lilly's new weight-loss pill, Foundayo, recorded 7,335 prescriptions in the U.S. during its fourth week of launch. This figure represents a modest initial uptake in a highly anticipated market, according to data from IQVIA.

Market Context and Competitor Analysis

Foundayo is entering the oral weight-loss drug market after its rival, Novo Nordisk’s Wegovy pill, which launched in January and holds a first-mover advantage. Despite the slower start, analysts note that investors are beginning to look beyond initial weekly script numbers as the sole barometer for Foundayo's long-term potential in the expanding obesity treatment sector.

Financial Projections and Outlook

To meet the consensus expectation of $160 million in second-quarter sales, analysts estimate Foundayo would need to reach approximately 22,000 prescriptions per week. Lilly executives reported that over 8,000 prescribers are now offering the drug, with more than 20,000 patients treated. Potential gaps in telehealth prescription data, which constitutes about 35% of launch volume, could lead to fluctuations in weekly reports.

Summary

While Foundayo's initial prescription numbers are modest, its future growth will depend on accelerating market adoption and overcoming early launch hurdles. The market will closely monitor whether the prescription volume can scale quickly enough to meet significant sales forecasts for the upcoming quarter.

FAQ

Q: How many Foundayo prescriptions were filled in its fourth week?
A: There were 7,335 prescriptions for Foundayo in the U.S. during its fourth week on the market.

Q: Who is Foundayo's main competitor?
A: Foundayo's primary competitor in the oral weight-loss drug market is Novo Nordisk's Wegovy pill.

Source: Investing.com